Anne Floquet
Impact in
- Reproductive Medicine top 0.05%
- Ovarian cancer diagnosis and treatment
- Oncology top 0.2%
- PARP inhibition in cancer therapy
Papers in
-
- Ovarian cancer diagnosis and treatment 83
-
- Endometrial and Cervical Cancer Treatments 31
- Uterine Myomas and Treatments 20
- Co-authors
- Gaëtan Marie MacGrogan (12 shared papers)M. Durand (6 shared papers)L. Mauriac (6 shared papers)A. Avril (5 shared papers)Marc Debled (4 shared papers)Francoise Bonichon (1 shared paper)Jean-Marie Dilhuydy (1 shared paper)Sabrina Croce (18 shared papers)
- Journals
- Annals of Oncology (39 papers)Gynecologic Oncology (21 papers)International Journal of Gynecological Cancer (19 papers)Journal of Clinical Oncology (9 papers)European Journal of Cancer (8 papers)
- Partner nations
- FranceUnited StatesItaly
In The Last Decade
Anne Floquet
180 papers receiving 12.2k citations
Anne Floquet's Hit Papers
Peers
Comparison fields: 5 of 131
- Reproductive Medicine 4.2k
- Oncology 6.7k
- Obstetrics and Gynecology 1.5k
- Cancer Research 1.2k
- Geriatrics and Gerontology 269
Countries citing papers authored by Anne Floquet
This map shows the geographic impact of Anne Floquet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne Floquet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne Floquet more than expected).
Fields of papers citing papers by Anne Floquet
This network shows the impact of papers produced by Anne Floquet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne Floquet. The network helps show where Anne Floquet may publish in the future.
Co-authors
The 25 scholars most cited alongside Anne Floquet, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 189 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer Hit paper breakdown → | 2018 | 2177 |
| 2 | Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial Hit paper breakdown → | 2017 | 1562 |
| 3 | Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2017 | 1394 |
| 4 | Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial Hit paper breakdown → | 2016 | 985 |
| 5 | 1999 | 370 | |
| 6 | 2012 | 358 | |
| 7 | 2017 | 345 | |
| 8 | Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial Hit paper breakdown → | 2022 | 339 |
| 9 | Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial Hit paper breakdown → | 2021 | 319 |
| 10 | 2014 | 269 | |
| 11 | 2018 | 217 | |
| 12 | 2013 | 191 | |
| 13 | 2012 | 173 | |
| 14 | Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2023 | 147 |
| 15 | 2012 | 121 | |
| 16 | 2007 | 119 | |
| 17 | 2018 | 110 | |
| 18 | 2012 | 101 | |
| 19 | 2015 | 98 | |
| 20 | 2016 | 88 |
About Anne Floquet
Anne Floquet is a scholar working on Reproductive Medicine, Obstetrics and Gynecology, Oncology, Genetics and Pulmonary and Respiratory Medicine, having authored 189 papers that have together received 12.5k indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (83 papers), PARP inhibition in cancer therapy (44 papers), Endometrial and Cervical Cancer Treatments (31 papers), BRCA gene mutations in cancer (22 papers), Uterine Myomas and Treatments (20 papers), Sarcoma Diagnosis and Treatment (8 papers), Intraperitoneal and Appendiceal Malignancies (8 papers) and Agriculture and Rural Development Research (5 papers). The work is most often cited by research in Reproductive Medicine (4.2k citations), Oncology (6.7k citations), Obstetrics and Gynecology (1.5k citations), Cancer Research (1.2k citations) and Geriatrics and Gerontology (269 citations). Anne Floquet has collaborated with scholars based in France, United States and Italy. Frequent co-authors include Gaëtan Marie MacGrogan, M. Durand, L. Mauriac, A. Avril, Marc Debled, Francoise Bonichon, Jean-Marie Dilhuydy, Sabrina Croce, Frédéric Guyon and Isabelle L. Ray-Coquard. Their work appears in journals such as Annals of Oncology, Gynecologic Oncology, International Journal of Gynecological Cancer, Journal of Clinical Oncology and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.